Insu Therapeutics gets U.S. patent allowance for buccal drug delivery

Victory Square Technologies Inc. (CSE: VST) (OTCQX: VSQTF) announced that its portfolio company, Insu Therapeutics Inc., has received a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application covering buccal peptide-delivery technology.

The allowance relates to U.S. Patent Application No. 18/513,373, titled "Mucoadhesive Pharmaceutical Dosage Form for Unidirectional Release of Peptide Therapeutic Particles." The application covers a layered dosage form designed to adhere to the inner cheek and direct the release of a peptide medicine toward underlying tissue. Formal patent issuance remains subject to payment of the required issue fee and completion of remaining formalities.

The allowance advances the intellectual-property foundation for two investigational products: InsuTab™, a buccal insulin formulation, and BuccaGLP™, a buccal semaglutide formulation. Both remain unapproved and are not available for commercial sale.

Insu holds an exclusive worldwide licence from the University of British Columbia to develop, market, commercialize and sublicense the technology. Insu has completed laboratory, cell-culture and rat studies at UBC as proof-of-concept work for its buccal insulin program.

Hydreight Technologies Inc., also a Victory Square portfolio company, completed a C$300,000 strategic investment in Insu in March 2026 and holds exclusive U.S. distribution rights for peptide therapeutics utilizing Insu's buccal technology, subject to successful development and regulatory approvals.

"This allowance is an important step in advancing the technology behind InsuTab and BuccaGLP," said Dr. Anubhav Pratap-Singh, board chair and co-founder of Insu Therapeutics. "Our focus is to translate the research into practical needle-free formulations for insulin and semaglutide."

Insu's commercial opportunity will depend on successful development, regulatory approval, manufacturing readiness and product adoption. Patent allowance does not establish clinical safety or efficacy or constitute regulatory approval.

You May Also Be Interested In

• Vistra Energy (VST) PT Lowered to $226 at Morgan Stanley
• Vistra Energy (VST) PT Lowered to $176 at Raymond James
• Jaguar Health's crofelemer shows early benefit in third rare gut disorder